Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

JERSEY CITY, N.J., Jan. 29, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a retrospective analysis of real-world data in the Journal of ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

The Japanese chemical company said Friday that it would sell unit Mitsubishi Tanabe Pharma to the U.S. investment company for about 510 billion yen, equivalent to $3.37 billion.

The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with ... to Bain Capital. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe ...

Bain Capital is in talks to acquire Mitsubishi Chemical Group’s pharmaceutical business in a potential multibillion-dollar deal, a person familiar with the matter said, a transaction that could ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.